HRA Proposes OTC Norgestrel Birth Control
HRA has worked with Ibis Reproductive Health, which supports the Free the Pill advocacy group, to conduct research for a norgestrel switch NDA.
You may also be interested in...
A round-up of the latest people moves in Europe's health and wellness markets: HRA Pharma's CEO David Wright steps down; Hofseth BioCare promotes Ødegård to lead the company; and the UK's Commission on Human Medicines appoints nine new members.
Consumer health product firms’ vistas include challenges of supply chain disruptions lingering from pandemic’s impact as well as potential for marketplace restrictions as additional varieties of the novel coronavirus spread. Clouds also include shifts in consumer spending, increases in costs caused by inflation and foreign exchange headwinds as the value of the US dollar strengthens against other currencies.
Data For Progress survey of 1,252 likely voters found “overwhelmingly support” from Democrats and Republicans for women’s access to daily oral contraceptives without a prescription and for FDA to allow OTC access.